Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-09-14
2011-10-18
Aeder, Sean (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
08039218
ABSTRACT:
A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and β-HCG. Also disclosed are kits containing agents for detecting the expression of these genes.
REFERENCES:
patent: 6057105 (2000-05-01), Hoon et al.
patent: 6248535 (2001-06-01), Danenberg et al.
patent: 6331393 (2001-12-01), Laird et al.
patent: 6428963 (2002-08-01), Danenberg et al.
patent: 6518416 (2003-02-01), Danenberg
patent: 6573052 (2003-06-01), Danenberg
patent: 6602670 (2003-08-01), Danenberg
patent: 6610488 (2003-08-01), Danenberg et al.
patent: 6613518 (2003-09-01), Danenberg
patent: 0 520 794 (1992-12-01), None
patent: 96/29430 (1996-09-01), None
patent: 99/10528 (1999-03-01), None
patent: 02/070571 (2002-09-01), None
patent: 02/070751 (2002-09-01), None
patent: 2004/045521 (2004-06-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Scholl et al (Feb. 2001, Cancer Research, 61:823-826).
Johansson et al (2000, Clinical Chemistry, 46(7): 921-927).
Hoon et al (US Patent 6,057,105; May 2, 2000).
Scholl et al (Feb. 2001, Cancer Research, 61:823-826) and.
Scoggins et al (Journal of Clinical Oncology, 2006, 24(18): 2849-2857).
Mocellin et al (TRENDS in Molecular Medicine, 2003, 9(5):189-195).
Tsao et al (Arch Dermatol, 2001, 137:325-330).
Gerber et al (Journal of Clinical Oncology, 2001, 19(4): 960-971).
Hilari et al (Ann Surg Oncol, 2009, 16(1): 177-185).
Tatilidil et al (Modern Pathology, 2007, 20: 427-434).
Denninghoff et al (Mol Diag, 2004, 8(4): Abstract).
Hoon et al (J Clin Oncol, 1995, 13(18): 2109-2116).
Bilchek et al., “Molecular Detection of Metastatic Pancreatic Carcinoma Cells Using a Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay”. Cancer. 88:1037-1044 (2000).
Balch et al., “Efficacy of an Elective Regional Lymph Node Dissection of 1 to 4 mm Thick Melanomas for Patients 60 Years of Age and Younger,” Ann. Surg. 1996; 224:255-63.
Balch et al., A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (stage I) Melanoma Treated in Alabama, USA and New South Wales, Australia, Ann. Surg. 196:677-684, 1982.
Bilchik, A.J., et al., “Molecular Staging of Early Colon Cancer on the Basis of Sentinel Node Analysis: a Multicenter Phase I Trial,” J. Clin. Oncol., 19: 1128-1136, 2001.
Bostick, P.J. et al., “Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase-Polymerase Chain Reaction in Early-Stage Melanoma Patients,” J. Clin. Oncol., 17:3238-3244, 1999.
Cascinelli et al., “Immediate or Delayed Dissection of Regional Nodes in Patients with Melanoma of the Trunk: a Randomized Trial,” WHO Melanoma Programme. Lancet, 1998; 351:796-6.
Clegg, R.M., “Fluorescence Energy Transfer.,” Curr. Opin. Biotech, 6: 103-110, 1995.
Cochran et al., “Occult Melanoma in Lymph Nodes Detected by Antiserum to S-100 Protein,” Int. J. Cancer, 1984; 34:159-63.
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma, J. Clin. Oncol., 16: 3635-3648, 2001.
Hatta et al. (Melanoma Research, Aug. 1999, 9(4): abstract).
Henderson, A.R., “Assessing Test Accuracy and Its Clinical Consequences: a Primer for Receiver Operating Characteristic Curve Analysis,” Ann Clin Biochem 1993; 30:521-29.
Hoon, D.S. et al., “Modulation of Human Melanoma Cells by Interleukin-4 and in Combination with gamma-Interferon or alpha-Tumor Necrosis Factor,” Cancer Res. 1991; 51: 2002-8.
Jemal et al., Cancer Statistics 2002, CA Cancer J. Clin., 52: 23-47, 2002.
Kawakami et al., “Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with In Vivo Tumor Rejection,” Proc. Natl. Acad. Sci., USA, 91: 6458-6462, 1994.
Keilholtz, Ulrich et al., “Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-time Reverse Transcriptase-Polymerase Chain Reaction,” Clinical Cancer Research, v. 10, Mar. 1, 2004, pp. 1605-1612.
Kocher et al., “Identification of Genes Differentially Expressed in Melanoma Sublines Derived from a Single Surgical Specimen Characterized by Different Sensitivity to Cytotoxic T-lymphocyte Activity,” Dept. of Surgery, Z.L.F., pp. 617-624.
Koyanagi et al., “Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial,” J. Clin. Oncol., 2005, 23(31):8057-8064.
Li et al., “Clinical Relevance of Molecular Staging for Melanoma: Comparison of RT-PCTR and Immunohistochemistry Staining in Sentinel Lymph Nodes of Patients with Melanoma,” Ann Surg. 2000; 231:795-803.
Masuda, N. et al., “Analysis of Chemical Modification of RNA from Formalin-fix Samples and Optimization of Molecular Biology Applications for Such Samples,” Nuc. Acid. Res. 19991; 27: 4436-43.
Mitas, M. et al., “Quantitative Real-time RT-PCR Detection of Breast Cancer Micrometastasis Using A Multigene Marker Panel,” Int. J. Cancer 2001; 93: 162-71.
Morton, D.L. et al., “Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma,” Arch. Surg. 127:392-399, 1992.
Morton, D.L. et al., “Intraoperative Lymphatic Mapping and Selective Cervical Lymphadenectomy for Early-Stage Melanomas of the Head and Neck,” J. Clin. Oncol. 1993; 11:1751-6.
Morton, D.L. et al., “Vaccine Therapy for Malignant Melanoma,” CA Cancer J. Clin. 1996; 46: 225-44.
Morton, D.L. et al., “Validation of the Accuracy of Intraoperative Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma: Multicenter Trial,” Multicenter Selective Lymphadenectomy Trial Group, Ann Surg. 1999; 230:453-63.
Morton et al., “Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy with a New Polyvalent Melanoma Vaccine,” Ann. Surg. 1992; 216:463-82.
O'Day, S.J. et al., “Maintenance Biotherapy for Metastatic Melanoma with Interleukin 2 and Granulocyte Macrophage-Colony Stimulating Factor Improves Survival for Patients Responding to Induction Concurrent Biochemotherapy,” Clin. Cancer Res. 2002; 8: 2775-81.
Rigel et al., “The Incidence of Malignant Melanoma in the United States: Issues as we Approach the 21st Century,” J. Am. Acad. Dermotol., 34: 839-847, 1996.
Sarantou, T. et al., “Melanoma-Associated Antigens as Messenger RNA Detection Markers for Melanoma,” Recent Results Cancer Res. 2001; 158: 78-92.
Schuster, R. et al., “Quantitative Real-Time RT-PCR for Detection of Disseminated Tumor Cells in Peripheral Blood of Patients with Colorectal Cancer Using Different mRNA Markers,” Ins. J. Cancer, v. 108, n. 2, pp. 219-227, Jan. 10, 2004.
Shirota, Y. et al., “ERCCI1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy,” J. Clin. Oncol. 2001; 19: 4298-304.
Shivers et al., “Molecular Staging of Malignant Melanoma: Correlation with Clinical Outcome,” JAMA 1998; 280:1410-5.
Sorensen, B.S. et al., “Quantification of Melanoma Cell-specific MART-I mRNA in Peripheral Blood by a Calibrated Competitive Reverse Transcription-PCR,” Clinical Chemistry 46:12, Sep. 26, 2000, pp. 1923-1928.
Specht, K. et al., “Quantitative Gene Expression Anaylsis in Microdissected Archival Tissue by Real-Time RT-PCR,”
Aeder Sean
Brooks & Kushman P.C.
John Wayne Cancer Institute
LandOfFree
Detection of cancer cells in body fluids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of cancer cells in body fluids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of cancer cells in body fluids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256685